FDA approves expanded indication for Lilly's Jaypirca

The US FDA has approved an expanded indication for Lilly's Jaypirca as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion. The regulatory decision is supported by data from the primary analysis of the Phase III BRUIN CLL-313 clinical study. Both CLL and SLL are slow-growing non-Hodgkin lymphomas that originate in lymphocytes. Credit: Saiful52/Shutterstock.com. The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)…

Source: Pharmaceutical Technology